Get started

Healthcare

Short the Red box :OWe have a good shorting Opp here. Its showing signs of reversal on most timeframes especially the larger ones such at the Month, Week and Daily. Noone can see 3-4 years into the future right? Well I'm no different so dont take this as financial advice more of just a hey this looks ok to me sort of thing. Ive taken the time to give you a Fan, a Triangle, and major resistance and support levels on larger time frames. Take the time do your own research but hope this helps guide some in the right direction Enjoy :) Purple is Monthy Yellow is weekly White is Heavy resistance/support lines due to large moves up/down Red Box: Short Area Overall Target it is 18-19, with potential to break through to 7-8
NYSE:BSXShort
by CryptoLeroy
Biogen Inc: Rare Long-Term Buy Opportunity.Biogen has lost over 30% of its value this month. Looking at the monthly chart, we have concluded that this is a rare investment opportunity as the current price is just above its 1M Support Zone. Historically we see that such an aggressive sell off recently took place in 2015 - 2016 and again the stock managed to recover almost reaching the 390 Resistance again. This pattern may be similar to the one the long term (~10 year) consolidation that took place after the 2000 peak. The price then traded sideways roughly within 17.00 - 71.00, providing a buy opportunity on every major pull back. We believe such an opportunity is presented now. Every dip near the 180 - 205 Support Zone can be bought with 350 - 390 as the Target Zone. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NASDAQ:BIIBLong
by InvestingScope
1
Pfizer PFE Possible Inverse Head & ShouldersAwaiting completion of a what looks to be a very nice inverse head and shoulders for NYSE:PFE . Notes: Bullish TA outlook - PFE broke out of a long-term head and shoulders recently, which is clearly visible on the weekly chart Buy Rating - 10 analysts cover NYSE:PFE . 5 Buy recommendations and 5 Hold recommendations. This has improve gradually over the past 3 months Analyst Price Target - Average $48.50 with a high of $55 and a low of $45 Trade: Buy - Strong breakout above $43.75 Stop Loss - Personally I would do any close under the 200 day MA but you could go as low as $40.33 Stop - Based on the size of the IH&S ($39.50 low to $43.75 neckline), TA theory indicates the stock should head to roughly $48, which just so happens to be right around all time highs (coincidence??)
NYSE:PFELong
by myfye13
Long in NVO Established There are several aspects to this chart- the wave analysis is certainly up for debate, but what remains is improving fundamentals. On this chart we have a corrective sequence ABC starting in 2014 and concluding in early 2017. On this chart, we can see the 30 day MA volume skyrockets in the beginning of 2017. This corresponds to the timing of the Obama administration focusing their healthcare attacks on big pharma, specifically drug pricing. We can even see a faint busted head and shoulders on this chart, with the right shoulder being broken by terrible guidance on earnings At the peak in 2015, we also see a peak in operating profit margin. Over the next 12 month fundamentals began to draw back with book value/share, liquidity ratios, and margins all slowly declining. As Obamacare got pushed through US congress (where over 50% of revenue is earned), the outlook looked bleak. Then the Man who lives above the Guchi Store was elected, and big pharma saw hope on the horizon and began surging higher. This was a false bull market though; margins and liquidity ratios were not improving for NVO. Then the surprise happened, President Trump began attacking pharma. Combined with the already volatile stock market NVO plunged to a correction right at the .618 fibonnaci level, if it maintains this as the low a perfect sign that the 2 impulse wave has just completed. Where we stand now: Novo Nordisk, one of the largest pill pushers was forced to lower outlooks with increasing competition from generics. With this pressure, the company has been forced to cut many US jobs and refocus R&D spending, rendering some patents and research useless. Over the last few years they've been forced to impair assets for use on their income statement, but NVO still maintains a 2.29 P/Tangible Book ratio, (better than peers: GSK, BMY, LLY). Gross margins have begun improving and P/S has landed at one of the lowest, if not the lowest level in the peer group. Improvement on the liquidity measures could send this stock flying, but most importantly is the deadlock that could ensue in congress. Recently one of the up-and-coming generics plunged as the FDA put a hold on their diabetes drug trial. I took a long position in NVO on 11/27 and plan on holding this until I either get stopped out at 44 or we rally to previous highs
NYSE:NVOLong
by scotch321
TORON INC-BIG UPSIDE-LONGTRON is a strong buy. I'm a Technician and only look at charts for my analysis. Analysis Method: Fibonacci & Elliot Waves Thesis: Healthcare is a fragmented market and will be consolidating over the next few years. Technically: Chart has just completed it's first Primary Wave Sequence + Correction. Here is a company overview: Toron Inc. Overview: Acquisition and development of healthcare companies Integrating access to electronic data interfaces for healthcare providers and payer systems Toron, Inc recognizes the tremendous opportunities present in the healthcare space. Zion research recently estimated “global demand for home healthcare market was valued at USD 228.90 billion in 2015 and is expected to generate revenue of USD 391.41 billion by 2021, growing at a CAGR of 9.40% between 2016 and 2021.” Toron, Inc targets the acquisition of additional healthcare focused companies which present excellent shareholder value. Its management has over thirty years combined experience in the healthcare space and it well positioned to identify and rapidly execute its acquisition plans. Toron, Inc intends to operate its business to maximize shareholder value and its management will ensure complete transparency in business operations. In today’s public market confidence is the key ingredient. Management will maintain communication of its operations and future acquisitions, mergers and results from its operations. Toron, Inc (The Company), is engaged in the acquisition and development of healthcare companies for the healthcare supplies and healthcare equipment markets. Management has been engaged in the healthcare technologies and will continue to develop additional markets through healthcare IT and other related entities. toroninc.com Trade Price: .006 Waves: Wave %'s: Indicators: ONB, CMF, Accum/Dist Spirals: Fib Time: Trade:
TLong
by FibMarketWatch